---
document_datetime: 2024-06-07 12:29:08
document_pages: 20
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/irbesartan-hydrochlorothiazide-teva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: irbesartan-hydrochlorothiazide-teva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 10.1981634
conversion_datetime: 2025-12-30 07:45:20.965755
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Irbesartan/Hydrochlorothiazide Teva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0064/G            | This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation | 04/06/2024                          |                                             | SmPC, Annex II and PL            |           |

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0063   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                          | 17/10/2023   | n/a        |             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|
| IB/0062/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 31/08/2023   | n/a        |             |
| IB/0061   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                           | 31/08/2023   | n/a        |             |
| IB/0059   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                        | 15/06/2023   | 15/09/2023 | SmPC        |
| IB/0058   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                        | 30/08/2022   | 15/09/2023 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| IA/0057   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                           | 05/07/2022   | n/a        |             |                                                                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------|
| IB/0056/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate | 22/12/2021   | n/a        |             |                                                                   |
| IB/0055   | B.II.d.1.g - Change in the specification parameters and/or limits of the finished product - Addition or replacement (excluding biological or immunological product) of a specification parameter wit its corresponding test method as a result of a safety or quality issue                                                                                                                                           | 29/07/2021   | 01/07/2022 | Annex II    | Update of Annex II of the product information to lift condition D |
| IB/0054/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                       | 29/06/2021   | 01/07/2022 | SmPC and PL |                                                                   |

<div style=\"page-break-after: always\"></div>

|           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0051/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 12/05/2021 | n/a |

<div style=\"page-break-after: always\"></div>

| IAIN/0052/G   | This was an application for a group of variations. B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 10/05/2021   | 01/07/2022   | SmPC and PL     |                                                                                                          |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|----------------------------------------------------------------------------------------------------------|
| IAIN/0053     | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 06/05/2021   | 01/07/2022   | Annex II and PL |                                                                                                          |
| A31/0041      | The European Commission triggered a referral under Article 31 of Directive 2001/83/EC and requested the CHMP to assess the impact of nitrosamine impurities on the benefit-risk balance of valsartan-containing medicinal products and to issue a recommendation on whether the relevant marketing authorisations should be maintained, varied, suspended or revoked. During the CHMP plenary meeting in September 2018, the scope of the referral has been widened to include all sartans with a tetrazole group in their molecular structure (candesartan, irbesartan, losartan, olmesartan and valsartan). The CHMP Opinion was issued on 31 January 2019 and the Commission Decision was issued on 2 April 2019. In a letter dated 29 July 2020, the European Commission requested the EMA to assess the impact of the outcome of the Article 5(3) assessment on | 12/11/2020   | 19/02/2021   | Annex II        | Please refer to the assessment report: Irbesartan/Hydrochlorothiazide Teva EMEA/H/A- 31/1471/C/1112/0041 |

<div style=\"page-break-after: always\"></div>

|           | adopted on 25 June 2020 on the CHMP's opinion of 31 January 2019 for the scientific assessment and review under Article 31 of Directive 2001/83/EC regarding angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (EMEA/H/A-31/1471). The CHMP was requested to give its recommendation whether the conditions of the Marketing Authorisations should be varied.                                                             |            |            |                 | nitrosamines   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------|
| IA/0050   | A.7 - Administrative change - Deletion of sites                                                                                                                                                                                                                                                                                                                                                                                                    | 21/12/2020 | 01/07/2022 | Annex II and PL | manufacturing  |
|           | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition) | 18/09/2020 | n/a        |                 | IAIN/0049/G    |
| IA/0048   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                               | 10/08/2020 | n/a        |                 |                |
| IAIN/0047 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                     | 19/06/2020 | 01/07/2022 | SmPC and PL     |                |

<div style=\"page-break-after: always\"></div>

| IA/0046/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.z - Changes in the manufacturing process of                                                                                                                                        | 10/10/2019   | n/a        |                        | the AS - Other variation   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|----------------------------|
| IB/0045     | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                 | 08/08/2019   | 01/07/2022 | Annex II               |                            |
| IA/0044/G   | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate approved manufacturer | 08/03/2019   | n/a        |                        | from an already            |
| IAIN/0043   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                              | 11/12/2018   | 11/04/2019 | SmPC and PL            |                            |
| IB/0042     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                | 25/10/2018   | 11/04/2019 | SmPC, Labelling and PL |                            |

<div style=\"page-break-after: always\"></div>

| IB/0038   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                      | 08/11/2017   | n/a        |                        |                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------|
| IB/0040   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                              | 07/11/2017   | 18/10/2018 | SmPC, Labelling and PL |                 |
| IB/0039/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate approved manufacturer | 23/10/2017   | n/a        |                        | from an already |
| IA/0037   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                 | 03/08/2017   | n/a        |                        |                 |
| IA/0036   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                  | 19/06/2017   | n/a        |                        |                 |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                           | 07/04/2017   | n/a        |                        | IA/0035   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------|
| IA/0034   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                          | 27/10/2016   | n/a        |                        |           |
| IA/0033   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                        | 23/03/2016   | 16/02/2017 | Annex II and PL        |           |
| IB/0032   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                           | 11/03/2016   | n/a        |                        |           |
| T/0031    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                  | 26/03/2015   | 05/05/2015 | SmPC, Labelling and PL |           |
| IB/0030   | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                              | 30/03/2015   | n/a        |                        |           |
| IA/0029/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate | 17/03/2015   | n/a        |                        |           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | - Submission of a new/updated or of Ph. Eur. Certificate of Suitability to the Ph. Eur. Monograph - Updated certificate an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                 | B.III.1.a.2 deletion relevant from   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------|
| IB/0028/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits to in-process tests or limits | 19/12/2014 | 05/05/2015 | Annex II and PL | B.II.b.5.z - Change                  |

<div style=\"page-break-after: always\"></div>

| product - Other variation B.II.b.5.z - Change to applied during the manufacture product - Other variation B.II.e.7.a - Change in components or devices dossier) - Deletion of a B.II.e.2.b - Change in and/or limits of the immediate finished product - Addition parameter to the specification test method B.II.e.2.c - Change in and/or limits of the immediate finished product - Deletion specification parameter parameter) B.II.e.2.b - Change in and/or limits of the immediate finished product - Addition parameter to the specification test method B.II.e.2.b - Change in and/or limits of the immediate finished product - Addition parameter to the specification test method B.II.e.2.b - Change in and/or limits of the immediate finished product - Addition parameter to the specification   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        |                                                                          |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------|
| R/0024    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 26/06/2014 | 11/11/2014 | SmPC, Labelling and PL | The CHMP recommends that the renewal be granted with unlimited validity. |
| IB/0027/G | This was an application for a group of variations. B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 07/11/2014 | n/a        |                        |                                                                          |

<div style=\"page-break-after: always\"></div>

|          | material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                                                                                                                                                                |            |            |             |                                                                                                                                    |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------|
| IB/0026  | B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 27/10/2014 | n/a        |             |                                                                                                                                    |
| A31/0019 | On 17 April 2013, further to the emergence of new evidence from the scientific literature on dual RAS blockade therapy and given the seriousness of the identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of Council Directive 2001/83/EC, requesting the Pharmacovigilance Risk Assessment Committee (PRAC) to issue a recommendation on the benefit- risk of dual RAS blockade therapy through the combined use of angiotensin-converting enzyme inhibitors (ACE-inhibitors), angiotensin II receptor blockers (ARBs) or aliskiren and to determine whether any regulatory measures should be taken on the marketing authorisations of the products involved in this procedure. | 22/05/2014 | 04/09/2014 | SmPC and PL | For further information please refer to the Renin- angiotensin-system (RAS)-acting agents Article 31 referral - Assessment report. |

<div style=\"page-break-after: always\"></div>

| IB/0023/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a        | 15/01/2014   | 04/09/2014   | SmPC, Annex II, Labelling and PL   |
|-------------|-------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|
| IA/0022     | A.7 - Administrative change - Deletion of manufacturing sites                                               | 06/12/2013   | 04/09/2014   | Annex II and PL                    |
| IB/0021     | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold | 28/06/2013   | n/a          |                                    |

<div style=\"page-break-after: always\"></div>

|           | compared to the currently approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |      |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|
| IB/0020   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 27/06/2013 | 13/12/2013 | SmPC |
| IAIN/0018 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 28/05/2013 | n/a        |      |
| IB/0017/G | This was an application for a group of variations. B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 01/03/2013 | n/a        |      |

<div style=\"page-break-after: always\"></div>

| IAIN/0016/G   | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)   | 21/11/2012   | 13/12/2013   | SmPC, Labelling and PL   |                       |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------|
| II/0014/G     | This was an application for a group of variations. addition of a new route of synthesis for the active substance Irbesartan with change to the specification and methods and addition of a manufacturing site for the new route of synthesis. B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product the manufacturer of AS or of a                                                                                                                                                                                                                                                                                                                                                   | 15/11/2012   | 15/11/2012   |                          | B.I.a.1.a - Change in |

<div style=\"page-break-after: always\"></div>

|             | material/reagent/intermediate for AS - The manufacturer is part of the same group as the currently approved                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        | starting proposed pharmaceutical manufacturer   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------|
| IAIN/0015/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 31/07/2012 | 29/10/2012 | SmPC, Labelling and PL | site                                            |
| IB/0013     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 19/06/2012 | 29/10/2012 | SmPC and PL            |                                                 |
| IB/0012     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 19/06/2012 | 29/10/2012 | SmPC and PL            |                                                 |

<div style=\"page-break-after: always\"></div>

|           | product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                         |            |            |                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IB/0011   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size                               | 11/05/2012 | n/a        |                 |
| IB/0010   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                               | 10/05/2012 | 29/10/2012 | SmPC            |
| IA/0009   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) | 26/09/2011 | n/a        |                 |
| IA/0008   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                       | 19/09/2011 | n/a        | Annex II and PL |
| IA/0007   | B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer         | 07/02/2011 | n/a        |                 |
| IA/0006   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) | 04/08/2010 | n/a        |                 |
| IA/0005/G | This was an application for a group of variations.                                                                                                                                      | 09/06/2010 | n/a        |                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.a.2.a - Change in the shape or dimensions of the pharmaceutical form - Immediate release tablets, capsules, suppositories and pessaries B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0004/G | This was an application for a group of variations. - To change the specifications of the acitve substance to comply with Ph. Eur. - To change the batch size of the finished product. - To change the dimensions of the pharmaceutical form. - To add a new supplier of aluminium foil for the primary packaging of the finished product. B.III.2.a.1 - Change of specification('s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.a.2.a - Change in the shape or dimensions of the pharmaceutical form - Immediate release tablets, capsules, suppositories and pessaries B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier | 01/06/2010 | n/a |

<div style=\"page-break-after: always\"></div>

| IB/0003/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                              | 12/05/2010   | n/a   | SmPC and PL     |                    |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------|--------------------|
| IB/0002     | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms IA_08_b_02_Change in BR/QC testing - repl./add. for BR - incl. BC/testing | 05/03/2010   | n/a   | Annex II and PL | manuf. responsible |
| IA/0001     | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                        | 11/01/2010   | n/a   |                 |                    |